CCI15106 (GSK)

CCI15106 is an investigational inhaled formulation of ribavirin, a broad-spectrum nucleoside antiviral agent, developed by GSK for the treatment of chronic obstructive pulmonary disease (COPD). The drug utilizes Particle Replication In Nonwetting Templates (PRINT) technology to create uniform, engineered particles designed for efficient delivery to the deep lung via a dry-powder inhaler. The therapeutic rationale is to treat or prevent viral respiratory infections, which are the primary drivers of acute COPD exacerbations. By delivering ribavirin directly to the respiratory tract, CCI15106 aims to achieve high local antiviral concentrations while minimizing the systemic toxicity typically associated with oral or intravenous ribavirin administration.

Other names

inhaled ribavirinribavirin-PRINT-CFIribavirin-PRINT-IP